Benefits of nucleos(t)ide analog treatments for hepatitis B virus-related cirrhosis

Table 3 Effects of treatment with nucleos(t)ide analogs in patients with decompensated cirrhosis

Ref.	Nucleos(t)ide	Patient number	Treatment duration	Improvement ratio of Child-Pugh score	Cumulative survival rate3
Villeneuve et al[18]	LAM (100 mg or 150 mg)	35 (CPB: 10, CPC: 25)	Mean: 19 mo	62.9% (22/35)1	1 yr: 78%4
					2 yr: 63%4
Kapoor et al[19]	LAM (150 mg)	18 (CPB: 14, CPC: 4)	Mean: 17.9 mo (range: 9-31 mo)	CPB to CPA: 50% (4/14)	No deaths attributed to liver disease
				CBC to CPB: 50% (2/4)
Yao et al[20]	LAM (150 mg)	13 (CPB: 0, CPC: 13)	Mean: 17.5 mo (range: 3-39 mo)	69% (9/13)2	Not described
Hann et al[22]	LAM (100 mg)	75 (CPA: 4, CPB: 28, CPB: 43)	Mean: 12.7 mo (range: 0.5-33 mo)	31% (23/75)1	Not described
Tseng et al[23]	LAM (100 mg)	30 (CPB: 16, CPC: 14)	Mean: 39.7 mo (range: 3-128 mo)	CPB to CPA: 62.5% (10/16)	1 yr 70%4
				CBC to CPB: 35.7% (5/14)	2 yr 66%4
					3 yr 55%4
					5 yr 55%4
Bae et al[24]	LAM (100 mg)	17 (CPB: 12, CPC: 5)	Mean: 28 mo (range: 14-42 mo)	CPB to CPA: 83% (10/12)	Not described
				CBC to CPB (1/5) or CPA (3/5): 80% (4/5)
Shim et al[25]	ETV (0.5 mg)	55 (mean CP score 8.1 ± 1.7)	12 mo	49% (27/55)1	12 mo: 87.1%
					24 mo: 83.0%
Hyun et al[26]	LAM (100 mg)	86 (CPB: 45, CPC: 41)	Mean: 2 yr	Mean Child-Pugh score	1 yr
	ETV (0.5 mg)			Baseline	LAM: 92.4%
				LAM: 9.5, ETV: 9.6	ETV: 90.7%
				12 mo	3 yr
				LAM: 6.7, ETV: 6.6	LAM: 86%4
					ETV: 76%4
Liaw et al[27]	TDF (300 mg)/FTC (200 mg) + TDV (300 mg)/ETV (0.5 mg or 1 mg)	112 (median CP score: 7, range: 6-9)	48 wk	TDF: 25.9% (7/27)1	Not described
				FTC/TDF: 48.0% (12/25)1
				ETV: 41.7% (5/12)1
Chan et al[29]	LAM (100 mg), TdT (600 mg)	228 (CPS < 7: 18, CPS 7-9: 155, CPS 9 <: 55)	52-104 wk	52 wk	52 wk
				LAM: 38.6% (44/114), TdT: 31.6% (36/114)1	LAM: 88%, TdT: 94%
				104 wk	104 wk
				LAM: 40.4% (46/114 ), TdT: 38.6% (44/114)1	LAM: 79%, TdT: 87%

¹Improvement of Child-Pugh score was defined as a decrease in the CPS greater than or equal to 2-points;

²Improvement of Child-Pugh score was defined as a decrease in the CPS greater than or equal to 3-points;

³Cumulative survival rates calculated by Kaplan-Meier method;

⁴Approximate value from the published graph. LAM: Lamibudine; ETV: Entecavir; TDF: Tenofovir; FTC: Emtricitabine; TdT: Telbivudine; CPB: Child-Pugh class B; CBC: Child-Pugh class C; CPS: Child Pugh score; CPA: Child-Pugh class A.